AN8025
Advanced Solid Tumors
Phase 1Active
Key Facts
About Adlai Nortye
Adlai Nortye is a clinical-stage biotech focused on developing innovative oncology therapies, with a core strategy of in-licensing and advancing mid-to-late-stage assets into new, high-need indications. Its most advanced candidate, buparlisib (AN2025), is in a pivotal global Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). The company aims to address significant unmet medical needs by modulating the tumor microenvironment and overcoming resistance to standard treatments like anti-PD-1 therapy.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |
| BI-1808 | BioInvent International | Phase 1/2a |
| GIGA-564 | GigaGen | Phase 1 |
| Venadaparib (IDX-1197) | Idience | Phase 1a |
| VET3-TGI | KaliVir Immunotherapeutics | Phase 1 |
| IT-141 (Etoposide IVECT™) | Intezyne | Phase 1 |
| NC318 | NextCure | Phase 1/2 |
| VisAcT (18F-AraG) Imaging in Solid Tumors | CellSight Technologies | Phase 1/2 |